Eight candidate names researched via App Store searches and domain checks using the Vercel domain availability tool. Injection-focused names were deprioritized. Pill-forward names scored higher for differentiation and ASO timing.
| Name | App Store (iOS) | Google Play | Domain (.com) | Domain (.app) | Trademark Risk | Score |
|---|---|---|---|---|---|---|
| GlpDay Recommended | Clear — no exact match | Clear | ✅ Available — $11.25/yr | ✅ Available — $14.99/yr | Low — generic category term | 9/10 |
| GlpCompanion | Clear — no exact match | Clear | ❌ Taken | ✅ Available — $14.99/yr | Low | 7/10 |
| SemaTracker | Clear — no exact match | Clear | ✅ Available — $11.25/yr | ✅ Available — $14.99/yr | Medium — "Sema" associated with Novo Nordisk drug names | 7/10 |
| PillFlow | Clear — no exact match found | Clear | ❌ Taken | ✅ Available — $14.99/yr | Low | 6/10 |
| OralGLP | Clear — no exact match | Clear | ❌ Taken | ✅ Available — $14.99/yr | Low | 6/10 |
| PillTrack | ❌ Generic — crowded space (Medisafe, MyTherapy, etc.) | ❌ Saturated | ❌ Taken | ❌ Taken | Medium — generic pill tracker names crowded | 3/10 |
| OzempicPill | ❌ HIGH RISK — Ozempic is Novo Nordisk trademark | ❌ HIGH RISK | Unverified | Unverified | HIGH — Ozempic is a registered trademark of Novo Nordisk | 1/10 |
| GlpPill | Clear | Clear | Unverified — not checked | Unverified — not checked | Low | 6/10 |
Short, daily cadence built into the name (pill users take it EVERY DAY vs injection users once a week). Both glpday.com and glpday.app are available at low cost. No trademark conflict. App Store shows zero exact matches. "GLP Day" signals pill routine, not shot routine — the entire positioning in 3 characters. Runner-up: GlpCompanion (.app available at $14.99/yr) if you want the longer brand name feel.
The oral GLP-1 era began officially on December 22, 2025, when the FDA approved Novo Nordisk's 25 mg oral Wegovy — the first-ever oral GLP-1 therapy for weight management. The pill launched in US pharmacies in early January 2026 at ~$149/month without insurance. This is a category-defining moment with no pill-native tracker app yet capturing it.
| Metric | Value | Source |
|---|---|---|
| Global GLP-1 drug market (2025) | $62.8B – $94B (range across analysts) | Fortune Business Insights, Polaris Market Research, 2025 |
| Global GLP-1 drug market (2026 projected) | $73B – $101.4B | Fortune Business Insights, InsightAce Analytic, 2026 |
| Oral GLP-1 market CAGR (2026–2035) | 35.05% CAGR | Towards Healthcare, 2025 |
| US GLP-1 users (2025 est.) | ~10–12.4M Americans actively taking GLP-1s | Statista / Truveta, 2025–2026 |
| US adults self-reporting GLP-1 use for weight loss | 12.4% of US adults (mid-2025) | Statista, 2025 |
| Oral semaglutide prescriptions surge (Dec 2025–Mar 2026) | +50% first-time prescribing jump | Truveta GLP-1 Prescription Trends Report, March 2026 |
| Weight loss / exercise app market (2025) | ~$1.15B, growing at 17.4% CAGR | Grand View Research / Business Research Company, 2025 |
| Health app revenue (2025) | $3.5B globally (+23.5% YoY) | Business of Apps, 2025 |
| Projected US GLP-1 patients by 2030 | ~25 million | JP Morgan, 2026 |
| Oral pills projected share of global weight-loss drug market by 2030 | ~24% ($22B) | Goldman Sachs analysts (via CNBC), 2026 |
Shotsy added a basic pill mode in March 2026 (v3.0) — but it's a bolted-on feature, not a rethink. The entire UX of Shotsy, Glapp, Pep, and MeAgain was designed around the weekly injection ritual: site rotation maps, weekly countdown timers, post-shot side effect windows. Pill users take semaglutide DAILY, must fast 30 min before eating, need protein-first meal reminders, and face daily muscle-loss risk. None of these apps were built for that workflow. The first-mover window to own "pill-first" is open right now.
Adults 28–55 who were needle-averse or didn't qualify for injectable GLP-1s, now newly starting oral Wegovy. Also includes existing injectable users transitioning to the pill. Predominantly female (60–65%), higher income (GLP-1 drugs are expensive even with insurance), and highly health-engaged on TikTok and Reddit r/Ozempic, r/WegovyWeightLoss.
The oral Wegovy launch in January 2026 is a genuine market inflection point. First-time GLP-1 prescriptions jumped 50% in the months following approval, largely driven by the pill (Truveta, March 2026). The pill removes the needle barrier that kept millions from starting — analysts project pills could capture 24% of the global weight-loss drug market by 2030 (Goldman Sachs). The companion app category is growing alongside it, but every current app was designed for injections. GlpDay is the bet that pill users want a purpose-built daily ritual tracker, not a shot tracker with a pill toggle added as an afterthought.
The GLP-1 tracker space has grown rapidly since 2024, but remains injection-centric. All five major competitors are now scrambling to bolt on pill support — none launched pill-first.
Free core tracking. Premium at $12.99/mo or $69.99/yr (raised from $29.99/yr in Feb 2025 — a 133% price increase). Premium unlocks medication level charts and advanced analytics. Raised $2.25M pre-seed, 2025.
100% organic word-of-mouth. Users shared Shotsy's colorful charts across Reddit and TikTok. No paid ads. Charts going viral in r/Ozempic and r/WegovyWeightLoss communities. Founded by Aja Beckett, 2024.
Est. $200K–$400K/mo (Unverified — based on ~1M users, low conversion rate at $12.99/mo premium). #1 Complaint: Massive price hike (from $29.99/yr to $69.99/yr) drove user exodus to Glapp. No cloud backup, data lost if phone changes. Pill support is bolted-on — not a first-class experience.
$9.99/mo flat. No free tier equivalent — this is a paid-first model. Also offers in-app compounded semaglutide at $123/mo and tirzepatide at $199/mo through US-based pharmacies. Rated #1 GLP-1 app for 2026 by several review sites.
Viral "capybara widget" for the home screen became a social media phenomenon. AI food photo logging drives TikTok demos. Strong SEO presence. Positioned as "#1 all-in-one GLP-1 app" across review sites.
Est. $250K–$500K/mo (Unverified — 286K+ users at $9.99/mo with moderate conversion). #1 Complaint: $9.99/mo feels expensive for what is essentially a habit tracker. Medication reseller model raises data privacy questions. Still injection-centric UX despite pill support claims.
Completely free — no subscription, no premium tier. Native iOS app + web browser access. Benefiting massively from Shotsy's price hike. Trustpilot reviews: "I cancelled my paid Shotsy subscription because Glapp is so easy to use." Revenue model: unclear/unknown — possibly pre-revenue.
Anti-Shotsy positioning. SEO articles targeting "Shotsy alternatives." Word-of-mouth driven by free pricing. Growing fast on the back of Shotsy's price backlash.
Est. $0 (pre-revenue / no monetization found). #1 Complaint: Being free is unsustainable — no backup, uncertain longevity. Still injection-focused UX. No protein or muscle-loss guidance. Limited pill-specific features.
Free download. Premium subscription approximately $10/mo (exact pricing unverified from web search). Tracks shots and pills, food macros, weight, side effects. AI photo food scanning. Solid food logging integration differentiates from pure shot trackers.
App Store optimization around medication names (Ozempic, Wegovy, Mounjaro). Community feedback loop — dev team is highly responsive to reviews. Organic growth via App Store discovery.
Unverified — too early/small for public estimates. #1 Complaint: Pill tracking exists but workflow still mirrors injection cadence. Protein/muscle goals not highlighted. Reminder UX designed around weekly shots, not daily pill timing.
Free tier + Premium at $79.99/yr, Premium+ at $99.99/yr ($24.99/mo). Added a GLP-1 content plan (free) — focuses on protein/fiber tracking and muscle-maintenance guidance. 200M+ user base but not a dedicated GLP-1 tracker.
20+ year brand recognition. Press coverage for GLP-1 integration launch. Cross-promotion to existing 200M user base. Content marketing blog targeting "how MyFitnessPal supports GLP-1 journey."
$100M+ ARR (public company data, est.). #1 Complaint: GLP-1 features are afterthought add-ons, not a first-class experience. No injection OR pill tracking — just nutrition guidance. Overkill for someone who just wants a daily pill reminder + protein goal.
Shotsy raised its annual price from $29.99 to $69.99 after their February 2025 funding round — a 133% increase that drove vocal backlash across Reddit and accelerated Glapp's rise. This is the exact dynamic that lets a new entrant enter at $29.99/yr ($3.99/mo) and position as "honest pricing for pill users." The window is open, the community is primed, and search intent for "Shotsy alternatives" is elevated. GlpDay should own that search term on day one.
The GLP-1 tracker space is competitive on core branded terms (Ozempic, Wegovy, semaglutide) but has significant whitespace on pill-specific and daily-routine keywords that no current app is targeting with intent. The oral pill launch creates new search queries that are currently underserved.
| Field | Recommended Text | Chars |
|---|---|---|
| App Name / Title | GlpDay: Oral GLP-1 Pill Tracker |
31 (trim to 30 if needed: "GlpDay — Oral GLP-1 Tracker") |
| Subtitle | Daily Pill · Protein · Muscle Guard |
35 (trim: "Pill Timing · Protein · Progress") |
| Primary Category | Health & Fitness | — |
| Secondary Category | Medical | — |
Zero apps are ranking for "oral GLP-1 pill tracker," "Wegovy pill app," or "fasting window GLP." Every current app's title and subtitle targets injections. Publishing first with pill-forward keywords creates a 6–12 month first-mover ranking advantage before competitors retool their metadata. In-App Events for "Oral Wegovy Pill Support Launch" would trigger editorial consideration from Apple's Health team.
Market size is exceptional: 10–12M active GLP-1 users in the US, growing 50% in new prescriptions after the January 2026 oral pill launch, on a trajectory to 25M by 2030. Differentiation is genuinely high: every existing app was built for weekly injections and lacks the daily pill workflow (30-min fasting reminder, protein-first meal nudges, daily muscle-loss tracking). Monetization is proven in the category — Shotsy's $69.99/yr and MeAgain's $9.99/mo both convert. Positioning at $29.99/yr ($3.99/mo) undercuts Shotsy and adds real price-value contrast. Technical feasibility is high — this is a local-first SwiftUI app with notifications, HealthKit, and simple charts. No ML needed for MVP.
| Factor | Assessment | Impact |
|---|---|---|
| Biggest Risk | Shotsy or MeAgain ships a polished pill-native mode before you launch. Shotsy already added basic pill support in March 2026 v3.0. Speed to market is critical — you need to be in the App Store within 60–90 days. | High urgency |
| Second Risk | Orforglipron (Foundayo, approved April 2026) does NOT require a fasting window — if it dominates, one core differentiator (30-min timing) loses relevance. Mitigate: keep protein/muscle as the primary differentiator, not just timing. | Medium |
| Biggest Opportunity | Shotsy's 133% price increase (to $69.99/yr) has created a vocal user migration wave. Owning "Shotsy alternative + pill-first" positions GlpDay at the exact point where demand and dissatisfaction intersect. | Very high |
| Second Opportunity | Apple Health editorial love. A new category of pill-era GLP-1 apps doesn't exist yet — a polished app launching in Q2 2026 has a realistic shot at an "App of the Day" or "New We Love" feature tied to the Wegovy pill news cycle. | High |
| Growth Lever | TikTok and Reddit communities are the organic distribution channels. GLP-1 influencers actively documenting pill journeys (vs injection journeys). A fasting-window countdown widget for the home screen is inherently shareable — the TikTok demo writes itself. | Very high |
| Sustainability | Pill market grows regardless of which specific drug wins. Whether Wegovy pill, orforglipron, or future oral GLP-1s dominate, a daily pill ritual tracker has evergreen utility as long as GLP-1 prescriptions keep rising. | Strong |
Register in App Store Connect before building. Claim glpday.com ($11.25/yr) and glpday.app ($14.99/yr) immediately.
7-day free trial. Free tier: pill log + basic reminder. Premium: protein goals, muscle score, fasting timer widget, progress charts, data export. Positioned below Shotsy ($69.99/yr) and MeAgain ($9.99/mo).
@Observable for state. StoreKit 2 for subscriptions. HealthKit for weight + steps read. Local notifications for pill timing. SwiftData for persistence. No backend needed for MVP.
Needle-averse adults starting Wegovy pill in 2026. Motivated but confused by complex pill protocol. Willing to pay for simplicity, accountability, and progress visibility. Heavy TikTok and Reddit users in the GLP-1 communities.
| # | Feature | Why It Matters | Build Session |
|---|---|---|---|
| 1 | Fasting Window Timer One-tap "I took my pill" starts a 30-min countdown with a home screen Live Activity showing time remaining before you can eat. |
This is the core daily ritual pill users don't have. The Live Activity is the TikTok demo moment — nobody else has this. Solves the #1 behavioral compliance failure. | S1 |
| 2 | Daily Protein Goal Tracker Set a daily protein target (80–120g recommended for GLP-1 users). Quick-log high-protein foods with one tap. Streak tracking for protein goals hit. |
Muscle loss is GLP-1's dirty secret — 25–40% of weight lost comes from lean mass. No injection-era app foregrounds this. Protein tracking in a pill-first context is the entire health differentiator. | S2 |
| 3 | Pill Log + Titration Timeline Daily pill check-in. Dose titration calendar (3mg → 7mg → 14mg → 25mg). Visual timeline of your GLP-1 journey with milestones. |
Oral Wegovy has a 16-week titration schedule. Users need to know where they are. No competing app visualizes this for the pill specifically. | S2 |
| 4 | Muscle Guard Score Weekly composite score (protein targets met, resistance training logged, weight change rate). Flags if you're losing weight too fast (muscle-loss risk). |
No app in the space has this. Creates a premium retention hook. The "muscle guard" concept is brand-sticky and highly shareable — "My muscle score went from 42 to 78 in 4 weeks." | S4 |
| 5 | Progress Charts + HealthKit Sync Weight loss curve, pill adherence rate, protein streak calendar. HealthKit integration for automatic weight and activity data. |
Visual progress is the reason Shotsy went viral (users sharing charts). GlpDay charts should be pill-era specific — adherence rate, fasting compliance, muscle score over time — not just weight. | S5 |
While Shotsy, MeAgain, and Glapp were built for weekly injection rituals, GlpDay is designed from the ground up for oral Wegovy users: a 30-minute fasting countdown the moment you take your pill, daily protein goals to protect muscle, and a Muscle Guard score that tells you if you're losing fat or muscle. $3.99/mo vs Shotsy's $5.83/mo. And you get a pill-first app instead of a shot tracker with a pill checkbox.